PL3393496T3 - Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych - Google Patents
Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnychInfo
- Publication number
- PL3393496T3 PL3393496T3 PL16880108.2T PL16880108T PL3393496T3 PL 3393496 T3 PL3393496 T3 PL 3393496T3 PL 16880108 T PL16880108 T PL 16880108T PL 3393496 T3 PL3393496 T3 PL 3393496T3
- Authority
- PL
- Poland
- Prior art keywords
- neurological
- agonist
- therapy
- long
- neurodegenerative conditions
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387319P | 2015-12-23 | 2015-12-23 | |
| PCT/US2016/068378 WO2017112889A1 (en) | 2015-12-23 | 2016-12-22 | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3393496T3 true PL3393496T3 (pl) | 2024-04-22 |
Family
ID=59091242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16880108.2T PL3393496T3 (pl) | 2015-12-23 | 2016-12-22 | Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123405B2 (pl) |
| EP (1) | EP3393496B1 (pl) |
| JP (2) | JP7026044B2 (pl) |
| KR (1) | KR102508651B1 (pl) |
| CN (1) | CN108697768B (pl) |
| AU (1) | AU2016379403B2 (pl) |
| DK (1) | DK3393496T5 (pl) |
| EA (1) | EA201891469A1 (pl) |
| ES (1) | ES2968038T3 (pl) |
| LT (1) | LT3393496T (pl) |
| PL (1) | PL3393496T3 (pl) |
| WO (1) | WO2017112889A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020323820B2 (en) * | 2019-07-29 | 2024-07-18 | Peptron, Inc. | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof |
| EP4005587A4 (en) * | 2019-07-29 | 2023-08-09 | Peptron, Inc. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION |
| MX2022004779A (es) * | 2019-11-06 | 2022-06-14 | Novo Nordisk As | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. |
| JP2024500410A (ja) * | 2020-12-16 | 2024-01-09 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 老化脳機能低下を逆転する方法 |
| CN113350488B (zh) * | 2021-07-16 | 2023-07-14 | 中国药科大学 | 口服降糖肽ohp在制备抗神经退行性疾病药物方面的应用 |
| US20240374691A1 (en) * | 2021-08-25 | 2024-11-14 | Neuraly, Inc. | Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection |
| EP4520350A1 (en) * | 2022-05-04 | 2025-03-12 | ImmunoForge Co., Ltd. | Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof |
| TW202410918A (zh) * | 2022-05-27 | 2024-03-16 | 韓商Ｄ＆Ｄ製藥科技股份有限公司 | 用於治療神經病症之組合物及方法 |
| WO2024229006A1 (en) | 2023-05-01 | 2024-11-07 | Neuraly, Inc. | Glucagon-like peptide-1 receptor agonist variants and methods thereof |
| CN119111471B (zh) * | 2023-06-27 | 2025-09-12 | 浙江大学 | 一种路易小体痴呆动物模型的构建方法和用途 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69938669D1 (de) | 1998-12-07 | 2008-06-19 | Sod Conseils Rech Applic | Analoge des glucagon ähnlichen peptides-1 (glp-1) |
| ES2343072T3 (es) | 1999-01-14 | 2010-07-22 | Amylin Pharmaceuticals, Inc. | Exendina para la supresion del glucagon. |
| CN1191273C (zh) | 1999-05-17 | 2005-03-02 | 康久化学公司 | 长效促胰岛肽 |
| US20050222036A1 (en) * | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| EP1313767A2 (en) | 2000-08-24 | 2003-05-28 | Thomas Jefferson University | Peptide with effects on cerebral health |
| AU2014277804B2 (en) | 2001-07-31 | 2016-12-01 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1 exendin-4 peptide analogs and uses thereof |
| AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| NL1021463C2 (nl) | 2002-09-16 | 2004-03-18 | Tno | Werkwijze voor het scheiden van rozetplanten. |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| CA2513307A1 (en) | 2003-02-19 | 2004-09-02 | Zheng Xin Dong | Analogues of glp-1 |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| EP2251353B1 (en) | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| EP1729795B1 (en) * | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2008516621A (ja) | 2004-10-18 | 2008-05-22 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン結合体 |
| ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
| AU2012202972A1 (en) | 2005-09-22 | 2012-06-14 | Biocompatibles Uk Ltd | GLP-1 fusion peptides, their production and use |
| WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
| AU2013201640A1 (en) | 2006-04-14 | 2013-04-11 | Mannkind Corporation | Glucagon-like peptide 1(GLP-1) pharmaceutical formulations |
| ATE444741T1 (de) | 2006-05-10 | 2009-10-15 | Biocompatibles Uk Ltd | Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung |
| KR100890989B1 (ko) | 2006-06-01 | 2009-03-31 | 이강춘 | 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도 |
| EP2057189B1 (en) | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| CN101195612B (zh) | 2006-12-05 | 2012-08-08 | 中国科学院上海药物研究所 | 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途 |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| US8420598B2 (en) | 2007-04-20 | 2013-04-16 | B & L Delipharm Corp. | Mono modified exendin with polyethylene glycol or its derivatives and uses thereof |
| US9353170B2 (en) * | 2007-06-08 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
| WO2010080578A1 (en) | 2008-12-18 | 2010-07-15 | Phasebio Pharmaceuticals, Inc. | Biologically active proteins activatable by peptidase |
| EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
| EP2440228B8 (en) | 2009-06-08 | 2023-02-22 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| JP5932642B2 (ja) | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| KR101112578B1 (ko) | 2009-07-16 | 2012-02-16 | 성균관대학교산학협력단 | 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법 |
| EP2482840A4 (en) | 2009-08-07 | 2013-06-26 | Mannkind Corp | VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME |
| CN102648384B (zh) | 2009-11-25 | 2014-06-18 | 大金工业株式会社 | 集装箱用制冷装置 |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| WO2011143209A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| SI2571510T1 (sl) | 2010-05-21 | 2019-02-28 | Xl-Protein Gmbh | Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe |
| EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| WO2012012352A2 (en) | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
| EP2621538B1 (en) | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
| CN102786590A (zh) * | 2011-05-19 | 2012-11-21 | 江苏豪森药业股份有限公司 | 分枝型peg修饰的glp-1类似物及其可药用盐 |
| US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| CN103906528A (zh) | 2011-06-24 | 2014-07-02 | 安米林药品有限责任公司 | 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法 |
| KR101357117B1 (ko) | 2011-06-28 | 2014-02-06 | 비앤엘델리팜 주식회사 | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 |
| JP6396211B2 (ja) | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
| WO2013009545A1 (en) | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| EP2578599A1 (en) | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclic analogs of GLP-1 and GLP-1 related peptides |
| WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| WO2013119650A1 (en) | 2012-02-06 | 2013-08-15 | Board Of Regents Of The University Of Nebraska | Delivery of biotherapeutics to the brain |
| EP2630965A1 (en) | 2012-02-24 | 2013-08-28 | Curatis Pharma GmbH | A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS) |
| WO2013148871A1 (en) | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Engineered polypeptides |
| EP2844269A4 (en) | 2012-03-28 | 2016-01-06 | Amylin Pharmaceuticals Llc | TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES |
| CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| RS57347B1 (sr) | 2012-06-21 | 2018-08-31 | Univ Indiana Res & Tech Corp | Analozi glukagona koji ispoljavaju aktivnost gip receptora |
| BR112015004418A2 (pt) | 2012-08-29 | 2017-07-04 | Mannkind Corp | composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit. |
| EP2895506A1 (en) | 2012-09-17 | 2015-07-22 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
| US20130303436A1 (en) | 2012-12-06 | 2013-11-14 | Stealth Peptides Internatioanl, Inc. | Peptide therapeutics and methods for using same |
| HRP20181300T1 (hr) | 2012-12-21 | 2018-10-05 | Sanofi | Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti |
| CA2897448A1 (en) | 2013-01-08 | 2014-07-17 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| SI2968471T1 (sl) | 2013-03-01 | 2017-11-30 | Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo |
| BR112015022936A2 (pt) | 2013-03-14 | 2017-07-18 | J Schentag Jerome | vesículas de colestossoma para a incorporação de moléculas em quilomícrons |
| CN105143250B (zh) | 2013-05-10 | 2020-11-03 | 北京华金瑞清生物医药技术有限公司 | 一种改造非抗体类蛋白产生结合分子的方法及其产品和一种长效glp-1受体激动剂 |
| MX2015016564A (es) | 2013-06-20 | 2016-04-15 | Novo Nordisk As | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. |
| AU2014286234A1 (en) | 2013-07-04 | 2015-12-17 | Novo Nordisk A/S | Derivatives of GLP-1 like peptides, and uses thereof |
| EP3033112B1 (en) | 2013-08-15 | 2020-10-07 | Novo Nordisk A/S | Glp-1 derivatives, and uses thereof |
| ES2927607T3 (es) | 2013-09-13 | 2022-11-08 | Scripps Research Inst | Agentes terapéuticos modificados y composiciones de los mismos |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086732A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
| EP3082797A4 (en) | 2013-12-18 | 2017-12-13 | The California Institute for Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| GB201404002D0 (en) | 2014-03-06 | 2014-04-23 | Imp Innovations Ltd | Novel compounds |
| AU2015269210A1 (en) | 2014-06-06 | 2016-12-08 | The California Institute For Biomedical Research | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| EP3169331A4 (en) | 2014-07-17 | 2018-01-17 | Jerome J. Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| EP3280723B1 (en) | 2015-04-08 | 2021-01-06 | Polyphor AG | Backbone-cyclized peptidomimetics |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016205488A1 (en) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| CN106110325A (zh) | 2016-06-08 | 2016-11-16 | 上海朗安生物技术有限公司 | 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用 |
| US20210353710A1 (en) * | 2020-03-05 | 2021-11-18 | The Johns Hopkins University | Glp-1r agonist and methods of treatment |
-
2016
- 2016-12-22 ES ES16880108T patent/ES2968038T3/es active Active
- 2016-12-22 WO PCT/US2016/068378 patent/WO2017112889A1/en not_active Ceased
- 2016-12-22 LT LTEPPCT/US2016/068378T patent/LT3393496T/lt unknown
- 2016-12-22 PL PL16880108.2T patent/PL3393496T3/pl unknown
- 2016-12-22 EP EP16880108.2A patent/EP3393496B1/en active Active
- 2016-12-22 DK DK16880108.2T patent/DK3393496T5/da active
- 2016-12-22 JP JP2018532682A patent/JP7026044B2/ja active Active
- 2016-12-22 US US16/065,445 patent/US11123405B2/en active Active
- 2016-12-22 EA EA201891469A patent/EA201891469A1/ru unknown
- 2016-12-22 CN CN201680082156.6A patent/CN108697768B/zh active Active
- 2016-12-22 AU AU2016379403A patent/AU2016379403B2/en active Active
- 2016-12-22 KR KR1020187020791A patent/KR102508651B1/ko active Active
-
2019
- 2019-12-10 JP JP2019223048A patent/JP2020059735A/ja active Pending
-
2021
- 2021-09-20 US US17/479,428 patent/US12233109B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3393496A1 (en) | 2018-10-31 |
| CN108697768B (zh) | 2022-07-22 |
| EP3393496A4 (en) | 2019-07-31 |
| JP2019500369A (ja) | 2019-01-10 |
| LT3393496T (lt) | 2023-12-11 |
| WO2017112889A1 (en) | 2017-06-29 |
| AU2016379403B2 (en) | 2020-03-12 |
| EP3393496B1 (en) | 2023-10-11 |
| KR20180096733A (ko) | 2018-08-29 |
| US20180369340A1 (en) | 2018-12-27 |
| KR102508651B1 (ko) | 2023-03-13 |
| EA201891469A1 (ru) | 2018-12-28 |
| ES2968038T3 (es) | 2024-05-06 |
| JP2020059735A (ja) | 2020-04-16 |
| US20220111010A1 (en) | 2022-04-14 |
| US12233109B2 (en) | 2025-02-25 |
| CN108697768A (zh) | 2018-10-23 |
| AU2016379403A1 (en) | 2018-07-19 |
| JP7026044B2 (ja) | 2022-02-25 |
| DK3393496T3 (en) | 2023-11-13 |
| CA3009506A1 (en) | 2017-06-29 |
| DK3393496T5 (da) | 2024-09-16 |
| US11123405B2 (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3393496T3 (en) | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions | |
| IL255423A0 (en) | Methods for treating neurodegenerative disease | |
| AU364560S (en) | Watch | |
| HUE051416T2 (hu) | Anilin elõállítása antranilát útján | |
| ZA201706882B (en) | Morphinan derivative | |
| ZA201802079B (en) | Long-acting adrenomedullin derivative | |
| GB201513845D0 (en) | Neurodegenerative disorders | |
| TWD174455S (zh) | 錶殼 | |
| GB2537419B (en) | Accumulation of floating-point values | |
| IL272670A (en) | Preparation of micro-electrodes | |
| GB201500534D0 (en) | Sexual stimulator | |
| AU201612149S (en) | Watch | |
| AU363942S (en) | Watch | |
| AU201612414S (en) | Watch | |
| GB2529964B (en) | Fencing | |
| GB201600893D0 (en) | Fencing bracket | |
| CA158030S (en) | Watch | |
| SG10201911436XA (en) | Watches | |
| PH32015000740S1 (en) | Watch | |
| PH32015000743S1 (en) | Watch | |
| GB201602152D0 (en) | Method of ground improvement | |
| AU362521S (en) | Watch | |
| AU362520S (en) | Watch | |
| AU362519S (en) | Watch | |
| AU362518S (en) | Watch |